Amirali Talasaz

Co-CEO Amirali Talasaz sells 210,000 shares (10% of holdings) for $23.1M via 12 scheduled transactions at GH

Amirali Talasaz executed 12 separate sales totaling 210,000 shares for $23,076,690.06 on 2026-05-20 via a pre-arranged 10b5-1 trading plan, reducing his holdings from 2,096,504 to 1,886,504 shares. This scheduled transaction occurred while the stock was up +32.8% over the prior 30 days and +15.4% over 90 days, trading at $118.95 versus the blended sale price of $109.89. The company remains unprofitable on an annual basis (net income $-112,075,000.00 for the most recent full fiscal year) despite strong revenue growth of +32.9% year-over-year and a market cap of $15.8B. Since this sale is part of a pre-arranged plan rather than a discretionary decision, it reflects scheduled portfolio actions rather than reactive decision-making tied to current market conditions.

Co-CEO Talasaz Amirali sold 50,000 shares for $5M; 6th sale at GH in 36 months with prior sells poorly timed at 30 days but well-timed at 90 days.

Talasaz Amirali, Co-Chief Executive Officer of Guardant Health, sold 50,000 shares valued at $5 million, reducing his indirect stake by that amount. This is the sixth open-market sale at the company within the past three years, part of a consistent pattern of dispositions with no offsetting open-market purchases in that window. Examining his prior sales at Guardant, the outcomes present a conflicting picture: all five earlier exits proved poorly timed in the short term as the stock gained in the following month, yet all five were well-timed over a longer three-month horizon as the stock subsequently fell. The company remains unprofitable on an annual basis despite posting revenue growth above 30 percent year-over-year, and the stock currently trades significantly below its 52-week high. This sale occurs against a backdrop where the insider has a long track record of selling but no recent open-market buying activity, suggesting steady position reductions rather than active portfolio management around company catalysts.

Co-CEO Talasaz sells 100,000 shares ($10.5M) at $104.21–$106.00; holdings drop 37.3% to 168,223 shares

Talasaz AmirAli, Co-Chief Executive Officer, executed 6 separate sales totaling 100,000 shares for $10,505,473.54 on 2025-12-08, reducing his holdings by 37.3% from 268,223 to 168,223 shares. The sales were priced at $104.21, $105.34, and $106.00 per share, yielding a blended average of $105.05, well above the current price of $102.62 and near the 52-week high of $111.25. At GH specifically, his prior 5 sells produced no well-timed outcomes: all 5 posted positive 90-day returns (ranging +20.0% to +30.1%), meaning the stock rose after each prior sale, suggesting his timing at this ticker has historically been poor. Guardant Health remains unprofitable on an annual basis (net income of $-92,725,000.00 in the latest quarter), though the company has achieved +31.0% annual revenue growth, which presents a contrast between operational expansion and continued losses that may warrant investor scrutiny of the sell's context.

Talasaz sells 100,000 GH shares for $5.1M at blended $50.88; holds 1.98M post-transaction

Co-Chief Executive Officer Talasaz AmirAli executed two separate sales totaling 100,000 shares for $5,087,629.74 on July 1, 2025, leaving him with 1,983,665 shares. The stock has appreciated 19.2% over 30 days and 19.4% over 90 days, near its 52-week high of $52.04; the transaction prices ($50.67 and $51.40) captured the recent momentum without exiting at depressed levels. His prior trades at Guardant Health show a mixed record: two recent sales (May 1–2) yielded negative 30-day returns of -21.2% and -19.5%, but measurable 90-day outcomes are not yet available for the three most recent sales (May 2, June 5, 6, and 9). His cross-ticker track record of 10 prior sells averaged -19.0% 30-day returns, suggesting a pattern of subsequent weakness, though outcome timing varies. The company remains unprofitable (net income $-95.2M in the latest quarter) despite 31.0% annual revenue growth, which creates underlying risk that current valuation momentum may not reflect fundamental health.

Guardant Health Co-CEO Talasaz sells 119,284 shares ($6.0M) across 3 tranches; persistent prior selling pattern at GH.

AmirAli executed 3 separate sales totaling 119,284 shares for $5,974,363.95 between June 5–9, 2025, reducing his holdings from 2,188,740 to 2,069,456 shares. This filing is material due to both volume (119.3K shares, -5.4% of pre-transaction holdings) and the executive's Co-CEO rank. His same-ticker history at Guardant Health reveals a consistent selling pattern: 5 prior sales all conducted on or near May 1–2, 2025, with post-sale 30-day returns of -19.5%, -16.6%, -18.0%, -14.8%, and -21.2%, suggesting these prior exits preceded near-term price weakness. The current transaction, filed at a blended price of $50.09, occurs while the stock sits at $49.53 (-0.8% from its 52-week high of $49.94), placing this sale near the upper end of recent range but not at local lows. The company remains unprofitable (net income $-95.2M in latest quarter) despite strong revenue growth of 31.0% year-over-year, creating a backdrop where an insider sale—particularly from a Co-CEO—invites scrutiny of management's assessment of near-term prospects.

Co-CEO Talasaz sold 120,716 shares for $5.9M across 7 transactions on May 1-2, 2025, at $49.18 average vs. $44.05 current price.

Talasaz AmirAli, Co-Chief Executive Officer, executed 7 separate sales totaling 120,716 shares for $5,936,572.03 on May 1–2, 2025, representing a 5.2% reduction in his 2.31M share position. The sales occurred at prices ranging from $47.67 to $52.57, with a blended average of $49.18—notably above the current market price of $44.05, reflecting an 11.8% decline from the 52-week high. This large equity reduction by a top executive at a $5.5B market-cap company warrants investor attention, particularly given the company's unprofitable status over its most recent full fiscal year (net income of -$95.2M) despite strong revenue growth of +31.0% annually. The timing of the sale, at prices substantially above current levels, provides a factual data point about valuation perception at the moment of execution.